Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07437079 · ClinicalTrials.gov registry record · Phase 1
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
A Phase 1 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT07437079: Recruiting Phase 1 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
NCT07437079 is a Phase 1 study of Obesity and Overweight that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 96 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07437079, a Phase 1 study of Obesity and Overweight, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.
Primary Outcome
Measure in number of events.
Conditions Studied
Interventions
- DRUG NNC6989-0001 A
- DRUG Placebo (NNC6989-0001 A)
Study Locations (1)
Kansas
- ICON Early Phase Services, LLC - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2027-01-21 |
| Phase | Phase 1 |
What NCT07437079 shows while recruiting
NCT07437079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which NNC6989-0001 A is the first listed.
NCT07437079 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT07437079 about?
NCT07437079 is a clinical study titled "A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity". This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 ...
What is the current status of trial NCT07437079?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2026-02-24. Estimated completion is 2027-01-21.
What conditions does trial NCT07437079 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07437079?
The interventions under investigation include: NNC6989-0001 A (DRUG), Placebo (NNC6989-0001 A) (DRUG).
Who is sponsoring clinical trial NCT07437079?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07437079 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07437079's enrollment target sits among peer trials
96 504th of 1053 higher than 545 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI